Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 463

1.
2.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
3.

Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.

Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.

Vaccine. 2010 Nov 23;28(50):7963-9. doi: 10.1016/j.vaccine.2010.09.066. Epub 2010 Oct 12.

PMID:
20946860
4.

Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.

Straight TM, Ottolini MG, Prince GA, Eichelberger MC.

Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44.

5.

Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration.

Budimir N, de Haan A, Meijerhof T, Gostick E, Price DA, Huckriede A, Wilschut J.

Influenza Other Respir Viruses. 2013 Nov;7(6):1202-9. doi: 10.1111/irv.12142. Epub 2013 Sep 16.

6.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
7.

A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model.

Jamali A, Sabahi F, Bamdad T, Hashemi H, Mahboudi F, Kheiri MT.

Clin Vaccine Immunol. 2010 Apr;17(4):683-7. doi: 10.1128/CVI.00445-09. Epub 2010 Feb 17.

8.

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.

Hessel A, Schwendinger M, Fritz D, Coulibaly S, Holzer GW, Sabarth N, Kistner O, Wodal W, Kerschbaum A, Savidis-Dacho H, Crowe BA, Kreil TR, Barrett PN, Falkner FG.

PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

10.

Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus.

Yang S, Niu S, Guo Z, Yuan Y, Xue K, Liu S, Jin H.

Virol J. 2013 Sep 22;10:291. doi: 10.1186/1743-422X-10-291.

11.

Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs.

Kappes MA, Sandbulte MR, Platt R, Wang C, Lager KM, Henningson JN, Lorusso A, Vincent AL, Loving CL, Roth JA, Kehrli ME Jr.

Vaccine. 2012 Jan 5;30(2):280-8. doi: 10.1016/j.vaccine.2011.10.098. Epub 2011 Nov 7.

PMID:
22067263
12.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

13.

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.

Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.

Arch Virol. 2006 May;151(5):921-31. Epub 2005 Nov 15.

PMID:
16292596
14.

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.

Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.

J Virol Methods. 2008 Dec;154(1-2):121-7. doi: 10.1016/j.jviromet.2008.08.011. Epub 2008 Sep 27.

PMID:
18789973
15.

Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations.

Furuya Y, Regner M, Lobigs M, Koskinen A, Müllbacher A, Alsharifi M.

J Gen Virol. 2010 Jun;91(Pt 6):1450-60. doi: 10.1099/vir.0.018168-0. Epub 2010 Feb 10.

PMID:
20147516
17.

Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.

Prabakaran M, Meng T, He F, Yunrui T, Qiang J, Lin RT, Kwang J.

Clin Vaccine Immunol. 2011 Sep;18(9):1582-5. doi: 10.1128/CVI.05114-11. Epub 2011 Jul 13.

18.

A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model.

Horimoto T, Takada A, Iwatsuki-Horimoto K, Kawaoka Y.

Vaccine. 2004 Jun 2;22(17-18):2244-7.

PMID:
15149783
19.

Intranasal immunization with live attenuated influenza vaccine plus chitosan as an adjuvant protects mice against homologous and heterologous virus challenge.

Wang X, Zhang W, Liu F, Zheng M, Zheng D, Zhang T, Yi Y, Ding Y, Luo J, Dai C, Wang H, Sun B, Chen Z.

Arch Virol. 2012 Aug;157(8):1451-61. doi: 10.1007/s00705-012-1318-7. Epub 2012 May 4.

PMID:
22552485
20.

Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J.

PLoS One. 2013 Jun 7;8(6):e63856. doi: 10.1371/journal.pone.0063856. Print 2013.

Supplemental Content

Support Center